Lutathera and pluvicto
Ended Awarded Last action
- Contract number
- W81K0025FA195
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $3,232,080
Award facts
- Contract value 100% obligated
- $3,232,079.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- JBSA FT SAM HOUSTON, TX 78234, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $56,104 | |
| Funding Only Action | $3,175,976 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded Novartis Pharmaceuticals Corporation a delivery order valued at $3.23 million on October 1, 2025, for the procurement of LUTATHERA (Lutetium Lu-177 dotatate) and PLUVICTO (Lutetium Lu-177 vipivotide tetra), specialized radiopharmaceutical cancer therapies. This delivery order represents an adjustment to quantities under contract line items 0001–0004 and updated unit pricing for items 0003–0004, with performance scheduled through September 30, 2026, at JBSA Fort Sam Houston, Texas. The contract is structured as a firm fixed-price delivery order with no small business set-aside designation, enabling Novartis to compete directly in the federal marketplace as a large pharmaceutical manufacturer.
This delivery order derives from Novartis' larger Indefinite Delivery Contract with the Defense Health Agency, established October 1, 2024, with a $26.1 million ceiling extending through September 30, 2029. The underlying indefinite delivery vehicle authorizes procurement of LUTATHERA and PLUVICTO for federal healthcare systems, supporting advanced oncology and nuclear medicine applications across the Department of Defense Health System. Novartis, a foreign-owned pharmaceutical manufacturer headquartered in East Hanover, New Jersey, serves as a major federal supplier of specialized cancer therapies and radiopharmaceuticals to both the Department of Veterans Affairs and Defense Health Agency, with extensive prior delivery orders and blanket purchase agreements totaling millions of dollars across multiple federal healthcare facilities.
Quick answers
Who was awarded contract W81K0025FA195?
W81K0025FA195 was awarded to Novartis Pharmaceuticals Corporation by Medical Command (Department of the Army) on October 1, 2025.
How much is contract W81K0025FA195 worth?
The government has obligated $3,232,080 on W81K0025FA195.
Which agency awarded contract W81K0025FA195?
Medical Command (Department of the Army) awarded W81K0025FA195, with funding from Defense Health Agency (Department of Defense).
Is contract W81K0025FA195 an order under another contract?
Yes. W81K0025FA195 is a delivery order under W81K0024D0004, an indefinite delivery contract.
Was contract W81K0025FA195 competed?
The extent of competition for W81K0025FA195 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award